Recombinant Human Transforming Growth Factor – beta 2 (rHuTGF-beta2)
Squence
Amino Acid Sequence
Synonyms
Accession Number
GeneID
Summary
Source
Mouse myeloma cell line, NS0
Molecular Weight
Biological Activity
Measured by its ability to inhibit the IL-4-dependent proliferation of HT‑2 mouse T cells. The ED50 for this effect is 0.025-0.25 ng/mL.
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from 0.2 um filtered concentrated solution in 35 % Acetonitrile and 0.1 % TFA.
Endotoxin
Less than 0.1 EU/ug of rHuTGF-beta2 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile 4 mM HCl to a concentration of 0.1 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriately buffered solutions.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
References
TGF-beta2 is a pleiotropic cytokine that regulates immune function, cellular proliferation, and epithelial-mesenchymal transition. It shows cross-species activity in the development of cardiac, lung, craniofacial, limb, eye, ear, and urogenital systems. Latent TGF-beta is activated by proteolytic cleavage of the mature cytokine from the latency-associated peptide. TGF-beta2 signaling involves the accessory receptor Betaglycan, TGF-beta RII, and a type I TGF-beta receptor, resulting in the activation of Smad signal transduction.
